



# MARKET RELEASE

19 February 2016

## **MGC Pharmaceuticals Limited**

### PRE-REINSTATEMENT DISCLOSURE

MGC Pharmaceuticals Limited ("Company") will be reinstated to official quotation as from 10 am AEDT on Tuesday, 23 February 2016 following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules.

The following information is released as pre-reinstatement disclosure.

1. Distribution schedule and top 20 holders.
2. Appendix 1A and Information Form and Checklist.
3. A copy of the Company's constitution.
4. Confirmations that:
  - a. there have been no material subsequent events to alter the Company's consolidated statement of financial position set out in the Company's prospectus dated 18 December 2015 and the Company's supplementary prospectus dated 11 February 2016 (together the "Prospectus");
  - b. MGC Pharma (UK) Ltd, a subsidiary of the Company, has completed the acquisition of MGC Pharmaceuticals d.o.o in Slovenia;
  - c. there are no legal, regulatory or contractual impediments to the Company undertaking the activities the subject of the commitments disclosed in the Prospectus; and
  - d. the Company is in compliance with the listing rules and in particular listing rule 3.1.
5. The full terms and conditions of the Company's Performance Shares.
6. Corporate governance statement.
7. MGC Pharma (UK) Limited's special purpose financial statements for the period 26 August 2015 to 30 September 2015.
8. An updated pro-forma balance sheet as at 31 January 2016 adjusted in respect of the loan facility with Sky Alba Pty Ltd.
9. The Company's security trading policy.
10. The Company's capital structure as at the date of reinstatement.

Security Code:                   MXC

Jeremy Newman

**Senior Adviser, Listings Compliance (Perth)**